Section Arrow
IDYA.NASDAQ
- IDEAYA Biosciences
Quotes are at least 15-min delayed:2025/07/21 06:56 EDT
Pre Market
Last
 --
-- (--)
Bid
20.5
Ask
24
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 21.59
-0.5 (-2.26%)
Day High 
22.555 
Prev. Close
22.09 
1-M High
23.06 
Volume 
549.68K 
Bid
20.5
Ask
24
Day Low
21.56 
Open
22.37 
1-M Low
20.5 
Market Cap 
1.93B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 22.12 
20-SMA 21.88 
50-SMA 20.64 
52-W High 44.42 
52-W Low 13.45 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.65/-2.59
Enterprise Value
1.95B
Balance Sheet
Book Value Per Share
11.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
7.00M
Operating Revenue Per Share
0.27
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 1.98 -0.3 -13.16%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.06 -1.015 -7.21%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.24 +0.4 +6.85%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.11 +0.19 +3.21%
Quotes are at least 15-min delayed:2025/07/21 06:56 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.